Clinical Trial Update: BrUOG 390: Neoadjuvant Treatment With Talazoparib [Phase 1]

View source ↗

Summary

Phase 1 neoadjuvant study of talazoparib in BRCA1/BRCA2 mutation-associated cancers ( ovarian/fallopian tube high-grade serous carcinoma) has been terminated wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High Grade Serous Carcinoma
• Ovarian Cancer

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Brown University | Conditions: BRCA1 Mutation, BRCA2 Mutation | Phase 1 | Status: TERMINATED | Results posted: 2023-10-12